Deep brain stimulation in patients on chronic antiplatelet or anticoagulation treatment
Authors:
Open Access
- 3 August 2021
- journal article
- research article
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 163 (10) , 2825-2831
Abstract
Background: In the aging society, many patients with movement disorders, pain syndromes, or psychiatric disorders who are candidates for deep brain stimulation (DBS) surgery suffer also from cardiovascular co-morbidities that require chronic antiplatelet or anticoagulation treatment. Because of a presumed increased risk of intracranial hemorrhage during or after surgery and limited knowledge about perioperative management, chronic antiplatelet or anticoagulation treatment often has been considered a relative contraindication for DBS. Here, we evaluate whether or not there is an increased risk for intracranial hemorrhage or thromboembolic complications in patients on chronic treatment (paused for surgery or bridged with subcutaneous heparin) as compared to those without. Methods: Out of a series of 465 patients undergoing functional stereotactic neurosurgery, 34 patients were identified who were on chronic treatment before and after receiving DBS. In patients with antiplatelet treatment, medication was stopped in the perioperative period. In patients with vitamin K antagonists or novel oral anticoagulants (NOACs), heparin was used for bridging. All patients had postoperative stereotactic CT scans, and were followed up for 1 year after surgery. Results: In patients on chronic antiplatelet or anticoagulation treatment, intracranial hemorrhage occurred in 2/34 (5.9%) DBS surgeries, whereas the rate of intracranial hemorrhage was 15/431 (3.5%) in those without, which was statistically not significant. Implantable pulse generator pocket hematomas were seen in 2/34 (5.9%) surgeries in patients on chronic treatment and in 4/426 (0.9%) without. There were only 2 instances of thromboembolic complications which both occurred in patients without chronic treatment. There were no hemorrhagic complications during follow-up for 1 year. Conclusions: DBS surgery in patients on chronic antiplatelet or anticoagulation treatment is feasible. Also, there was no increased risk of hemorrhage in the first year of follow-up after DBS surgery. Appropriate patient selection and standardized perioperative management are necessary to reduce the risk of intracranial hemorrhage and thromboembolic complications.Keywords
Funding Information
- Medizinische Hochschule Hannover (MHH)
This publication has 40 references indexed in Scilit:
- Pacemaker or Defibrillator Surgery without Interruption of AnticoagulationNew England Journal of Medicine, 2013
- Recurrent, Delayed Hemorrhage Associated with Edoxaban after Deep Brain Stimulation Lead PlacementCase Reports in Neurological Medicine, 2013
- Long‐term clinical outcome in meige syndrome treated with internal pallidum deep brain stimulationMovement Disorders, 2011
- Chronic deep brain stimulation in patients with tardive dystonia without a history of major psychosisMovement Disorders, 2010
- SUBCUTANEOUS HEPARIN FOR PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN DEEP BRAIN STIMULATION SURGERYNeurosurgery, 2009
- Delayed Thalamic Intracranial Hemorrhage in an Essential Tremor Patient following Deep Brain StimulationEuropean Neurology, 2008
- Incidence of symptomatic hemorrhage after stereotactic electrode placementJournal of Neurosurgery, 2007
- Thirty days complication rate following surgery performed for deep‐brain‐stimulationMovement Disorders, 2007
- Long-term deep brain stimulation in elderly patients with cardiac pacemakersJournal of Neurosurgery, 2005
- Hemorrhagic complication of stereotactic surgery in patients with movement disordersJournal of Neurosurgery, 2003